A major boost for biopharma manufacturing in the North

Biopharmaceuticals made in Schleswig-Holstein: In this interview, Richter BioLogics CEO Kai Pohlmeyer explains why the contract manufacturer has invested 100 million euros in the expansion of its plant in Bovenau and what this means for the Cluster Life Science Nord.

Business Nord|Innovation|Science & Translation HIV gene-editing therapy heads to the clinic

Provirex’ innovative genome editing therapy enables the elimination of persistent viral genomes from infected cells. The start-up is building a therapy hub in the future Science City Hamburg Bahrenfeld.

Science & Translation Gene and Cell Therapies: Shaping the National Strategy

The recently published National Strategy for Gene and Cell-Based Therapies is intended to link the players in this innovative field of medicine throughout Germany and to speed up the introduction of treatment approaches into clinical care. Four experts from Hamburg were involved in the development of the strategy. What is most important to them?

Science & Translation Stem cell medicine in the North: The report

When the experts meet in Hamburg in July for the most important global congress in stem cell research – the ISSCR Annual Meeting – many regional players from the Life Science Nord cluster will also be there. A guide to the region's major players in research and industry in the stem cell field.

Portrait AI and crystals: “We provide the blueprint for innovative drug design”

The start-up CrystalsFirst specializes in structural biological analyses of protein crystals for drug development. The team has been based at DESY in Hamburg-Bahrenfeld since 2022. In this interview, founder and CEO Serghei Glinca talks about the technology and the structural biology ecosystem in the North of Germany.

Networking|Portrait Our Chairwoman for Regulatory Affairs: Heike Wachenhausen

Heike Wachhausen has been our honorary chairwoman at Life Science Nord e.V. since autumn 2021. She is our trusted contact for all regulatory affairs issues.

AI and crystals: “We provide the blueprint for innovative drug design”

Portrait AI and crystals: “We provide the blueprint for innovative drug design”

The start-up CrystalsFirst specializes in structural biological analyses of protein crystals for drug development. The team has been based at DESY in Hamburg-Bahrenfeld since 2022. In this interview, founder and CEO Serghei Glinca talks about the technology and the structural biology ecosystem in the North of Germany.

Our Chairwoman for Regulatory Affairs: Heike Wachenhausen

Networking|Portrait Our Chairwoman for Regulatory Affairs: Heike Wachenhausen

Heike Wachhausen has been our honorary chairwoman at Life Science Nord e.V. since autumn 2021. She is our trusted contact for all regulatory affairs issues.

Kiel: Translating marine sciences into medicine

Innovation Kiel: Translating marine sciences into medicine

The BlueHealthTech alliance from Kiel wants to be able to combat chronic diseases before symptoms appear. They have been supported with 15 million euros in funding since 2021. Find out more here.

How Nordmark is on course for growth with biotechnology

Business Nord How Nordmark is on course for growth with biotechnology

Nordmark invests 20 million euros in biotechnology and enters into partnerships to accelerate processes. Its goals include the fight against cancer in children. Find out more here.

By category

A major boost for biopharma manufacturing in the North

A major boost for biopharma manufacturing in the North

Biopharmaceuticals made in Schleswig-Holstein: In this interview, Richter BioLogics CEO Kai Pohlmeyer explains why the contract manufacturer has invested 100 million euros in the expansion of its plant in Bovenau and what this means for the Cluster Life Science Nord.

HIV gene-editing therapy heads to the clinic

Business Nord|Innovation|Science & Translation HIV gene-editing therapy heads to the clinic

Provirex’ innovative genome editing therapy enables the elimination of persistent viral genomes from infected cells. The start-up is building a therapy hub in the future Science City Hamburg Bahrenfeld.

Gene and Cell Therapies: Shaping the National Strategy

Science & Translation Gene and Cell Therapies: Shaping the National Strategy

The recently published National Strategy for Gene and Cell-Based Therapies is intended to link the players in this innovative field of medicine throughout Germany and to speed up the introduction of treatment approaches into clinical care. Four experts from Hamburg were involved in the development of the strategy. What is most important to them?

Stem cell medicine in the North: The report

Science & Translation Stem cell medicine in the North: The report

When the experts meet in Hamburg in July for the most important global congress in stem cell research – the ISSCR Annual Meeting – many regional players from the Life Science Nord cluster will also be there. A guide to the region's major players in research and industry in the stem cell field.

AI and crystals: “We provide the blueprint for innovative drug design”

Portrait AI and crystals: “We provide the blueprint for innovative drug design”

The start-up CrystalsFirst specializes in structural biological analyses of protein crystals for drug development. The team has been based at DESY in Hamburg-Bahrenfeld since 2022. In this interview, founder and CEO Serghei Glinca talks about the technology and the structural biology ecosystem in the North of Germany.

Our Chairwoman for Regulatory Affairs: Heike Wachenhausen

Networking|Portrait Our Chairwoman for Regulatory Affairs: Heike Wachenhausen

Heike Wachhausen has been our honorary chairwoman at Life Science Nord e.V. since autumn 2021. She is our trusted contact for all regulatory affairs issues.

Popular

A major boost for biopharma manufacturing in the North

A major boost for biopharma manufacturing in the North

Biopharmaceuticals made in Schleswig-Holstein: In this interview, Richter BioLogics CEO Kai Pohlmeyer explains why the contract manufacturer has invested 100 million euros in the expansion of its plant in Bovenau and what this means for the Cluster Life Science Nord.

HIV gene-editing therapy heads to the clinic

Business Nord|Innovation|Science & Translation HIV gene-editing therapy heads to the clinic

Provirex’ innovative genome editing therapy enables the elimination of persistent viral genomes from infected cells. The start-up is building a therapy hub in the future Science City Hamburg Bahrenfeld.

Gene and Cell Therapies: Shaping the National Strategy

Science & Translation Gene and Cell Therapies: Shaping the National Strategy

The recently published National Strategy for Gene and Cell-Based Therapies is intended to link the players in this innovative field of medicine throughout Germany and to speed up the introduction of treatment approaches into clinical care. Four experts from Hamburg were involved in the development of the strategy. What is most important to them?

Stem cell medicine in the North: The report

Science & Translation Stem cell medicine in the North: The report

When the experts meet in Hamburg in July for the most important global congress in stem cell research – the ISSCR Annual Meeting – many regional players from the Life Science Nord cluster will also be there. A guide to the region's major players in research and industry in the stem cell field.